Nucleic Acids

DNA was prepared from cell line WM3623. WM3623 is a metastatic human melanoma cell line. This cell line was established from a right lymph node metastasis site in a 48-year-old male with level V metastatic malignant melanoma. This cell line contains a Q61K mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. WM3623 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3623. WM3623 is a metastatic human melanoma cell line. This cell line was established from a right lymph node metastasis site in a 48-year-old male with level V metastatic malignant melanoma. This cell line contains a Q61K mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. WM3623 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3623. WM3623 is a metastatic human melanoma cell line. This cell line was established from a right lymph node metastasis site in a 48-year-old male with level V metastatic malignant melanoma. This cell line contains a Q61K mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. WM3623 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3623. WM3623 is a metastatic human melanoma cell line. This cell line was established from a right lymph node metastasis site in a 48-year-old male with level V metastatic malignant melanoma. This cell line contains a Q61K mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. WM3623 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM3629. WM3629 is a metastatic human melanoma cell line that displays a mesenchymal and dendritic morphology. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a D549G mutation in the BRAF gene resulting in an amino acid substitution from aspartic acid to glycine at codon 549 (Asp549Gly). These cells also express G12D mutation in the N-RAS gene resulting in substitution of glycine with aspartic acid at codon 12 (Gly12Asp).WM3629 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM3629. WM3629 is a metastatic human melanoma cell line that displays a mesenchymal and dendritic morphology. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a D549G mutation in the BRAF gene resulting in an amino acid substitution from aspartic acid to glycine at codon 549 (Asp549Gly). These cells also express G12D mutation in the N-RAS gene resulting in substitution of glycine with aspartic acid at codon 12 (Gly12Asp).WM3629 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM3629. WM3629 is a metastatic human melanoma cell line that displays a mesenchymal and dendritic morphology. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a D549G mutation in the BRAF gene resulting in an amino acid substitution from aspartic acid to glycine at codon 549 (Asp549Gly). These cells also express G12D mutation in the N-RAS gene resulting in substitution of glycine with aspartic acid at codon 12 (Gly12Asp).WM3629 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3629. WM3629 is a metastatic human melanoma cell line that displays a mesenchymal and dendritic morphology. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a D549G mutation in the BRAF gene resulting in an amino acid substitution from aspartic acid to glycine at codon 549 (Asp549Gly). These cells also express G12D mutation in the N-RAS gene resulting in substitution of glycine with aspartic acid at codon 12 (Gly12Asp).WM3629 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3629. WM3629 is a metastatic human melanoma cell line that displays a mesenchymal and dendritic morphology. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a D549G mutation in the BRAF gene resulting in an amino acid substitution from aspartic acid to glycine at codon 549 (Asp549Gly). These cells also express G12D mutation in the N-RAS gene resulting in substitution of glycine with aspartic acid at codon 12 (Gly12Asp).WM3629 cells produce xenograft tumors when injected into immunocompromised mice.